PMV Pharmaceuticals, Inc. (PMVP): Total Assets
$116.56M
As of 2025-12-31
$82.07M
As of 2026-06-30
-24.5%
3-year compound annual growth
-20.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $116.56M | -39.1% | 2026-03-06, Balance as of period end |
| 2024-12-31 | $191.29M | -24.1% | 2026-03-06, Balance as of period end |
| 2023-12-31 | $252.15M | -6.7% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $270.31M | -18.5% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $331.57M | -9.3% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $365.53M | +254.8% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $103.03M | n/a | 2021-03-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $116.56M | -39.1% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $116.48M | -27.3% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $116.46M | -22.7% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $117.18M | +51.2% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $117.81M | +50.4% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $118.36M | -24.9% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $114.11M | +17.8% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $119.59M | -44.3% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $113.56M | +50.4% |
Compare PMVP, SGMT, AVTX, AARD side by side · Screen every company in Pharmaceutical Preparations ↗